Researcher
Alfons Verbruggen
- Disciplines:Medicinal products, Biomarker discovery and evaluation, Drug discovery and development, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Faculty of Pharmaceutical Sciences (Faculty)
Member
From1 Oct 2020 → Today - Radiopharmaceutical Research (Division)
Member
From1 Oct 1999 → 30 Sep 2019
Projects
1 - 10 of 10
- translational study of the modulation of fosfodiesterase type 10A expression by dopaminergic neurotransmission using molecular imagingFrom1 Jan 2013 → 31 Dec 2016Funding: FWO research project (including WEAVE projects)
- Oncocidia_the novel anticancer therapy: phase 0 clinical study.From1 Jan 2013 → 31 Dec 2013Funding: IOF - Industrial Research Fund
- Development and evaluation of PET ligands for the in vivo visualisation of phosphodiesterase type 5 (PDE5).From1 Jan 2012 → 31 Dec 2015Funding: FWO research project (including WEAVE projects)
- Synthesis and biological evaluation of carbon-11 and fluorine-18 labelled P2X7-receptor ligands for diagnosis of neurological diseases using positron emission tomographyFrom1 Oct 2011 → 30 Sep 2015Funding: FWO fellowships
- In vivo molecular imaging research (IMIR).From1 Nov 2010 → 31 Oct 2018Funding: BOF - Concerted Research Project from 1994
- Molecular and functional imaging as a pivotal tool for translational medicine in the field of neuroscience and oncology: a platform creating a bridge between basic research, clinical development and industrial application.From1 Oct 2010 → 30 Sep 2014Funding: IOF - Industrial Research Fund
- Preclinical validation and first in man study of PET radioligands for the cannabinoidreceptor type 2.From1 Jan 2010 → 31 Dec 2013Funding: FWO research project (including WEAVE projects)
- Synthesis and (pre)clinical evaluation of PET radioligands for in vivo visualization of phosphodiesterase 10, an enzyme involved in neurological and psychiatric disorders.From1 Oct 2009 → 30 Sep 2010Funding: BOF - Other initiatives
- Development of a radiolabelled probes for the in vivo visualisation of the TRPV1 receptor with PETFrom1 Oct 2008 → 24 Jan 2013Funding: IWT personal funding - strategic basic research grants
- Anti-kanker therapie versterkt door kleine radioactief gelabelde compounds met affiniteit voor necrosis (sRALNAC): een Prrof-of-Principle experiment ter ondersteuning van een nieuw patent aanvraag.From1 Jul 2008 → 30 Jun 2009Funding: IOF - Industrial Research Fund
Publications
11 - 20 of 124
- 18F-Labelling of biomolecules for PET(2016)
Authors: Frederik Cleeren, Guy Bormans, Alfons Verbruggen
- Recent Progress in Metal Catalyzed Direct Carboxylation of Aryl Halides and Pseudo Halides Employing CO2: Opportunities for 11C radiochemistry(2016)
Authors: Uta Funke, Joan Lecina, Alfons Verbruggen, Guy Bormans
Pages: 3692 - 3700 - Synthesis, biodistribution and in vitro evaluation of brain permeable high affinity type 2 cannabinoid receptor agonists [11C]MA2 and [18F]MA3(2016)
Authors: Koen Van Laere, Alfons Verbruggen, Guy Bormans
Pages: 431 - 431 - Preclinical evaluation of a P2X7 receptor selective radiotracer: PET studies in a rat model with local overexpression of the human P2X7 receptor and in non-human primates(2016)
Authors: Sofie Celen, Rik Gijsbers, Chris Van den Haute, Michel Koole, Wim Vanduffel, Koen Van Laere, Alfons Verbruggen, Zeger Debyser, Guy Bormans
Pages: 1436 - 1441 - Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients. Correlation of parameters during PRRT(2016)
Authors: Michel Koole, Kristof Baete, Karin Haustermans, Paul Clement, Kris Bogaerts, Alfons Verbruggen, Kristiaan Nackaerts, Eric Van Cutsem, Chris Verslype, Felix Mottaghy, et al.
Pages: 104 - 114 - Stratial phosphodiesterase 10A binding is altered secondary to chronic changes in dopamine neurotransmission(2016)
Authors: Sofie Celen, Michel Koole, Alfons Verbruggen, Koen Van Laere, Guy Bormans
Pages: 1510 - 1515 - Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission(2016)
Authors: Maarten Ooms, Sofie Celen, Michel Koole, Alfons Verbruggen, Koen Van Laere, Guy Bormans
Pages: 1 - 17 - Drug development in Alzheimer’s disease: the contribution of PET and SPECT(2016)
Authors: Lieven Declercq, Rik Vandenberghe, Koen Van Laere, Alfons Verbruggen, Guy Bormans
Pages: 1 - 27 - Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours(2016)
Authors: Sofie Van Binnebeek, Kristof Baete, Michel Koole, Felix Mottaghy, Paul Clement, Luc Mortelmans, Kris Bogaerts, Karin Haustermans, Kristiaan Nackaerts, Eric Van Cutsem, et al.
Pages: 900 - 9 - New chelators for low temperature Al(18)F-labeling of biomolecules(2016)
Authors: Frederik Cleeren, Joan Lecina, Emilie Billaud, Alfons Verbruggen, Guy Bormans
Pages: 790 - 8
Patents
1 - 4 of 4